Panmure Gordon restated their buy rating on shares of Venture Life Group PLC (LON:VLG) in a report issued on Wednesday. The brokerage currently has a GBX 128 ($1.67) target price on the stock.

Separately, Beaufort Securities reiterated a speculative buy rating on shares of Venture Life Group PLC in a research report on Monday, August 1st.

Shares of Venture Life Group PLC (LON:VLG) opened at 54.17 on Wednesday. Venture Life Group PLC has a one year low of GBX 43.00 and a one year high of GBX 81.92. The stock’s market capitalization is GBX 18.64 million. The company’s 50-day moving average is GBX 51.62 and its 200-day moving average is GBX 56.45.

Venture Life Group PLC Company Profile

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.